Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study.

Aakash Desai Jana G HashashGursimran S KochharFrancis A Farraye

Published in: Crohn's & colitis 360 (2023)

Our study did not show that Evusheld decreases the risk of COVID-19 in patients with IBD. Prevention of moderate-severe COVID-19 in these patients should focus on vaccination strategies and early COVID-19 therapies.

Keyphrases

coronavirus disease
sars cov
patients with inflammatory bowel disease
end stage renal disease
ejection fraction
respiratory syndrome coronavirus
chronic kidney disease
prognostic factors
high intensity
patient reported outcomes
patient reported